followers 12 popularity
6
following 1

following  view all

Groups
Arslan is not in any groups
Arslan

Global Fibrosarcoma Market Inclinations & Development Status Highlighted for the Forecast Period between 2017 and 2026

Dec 13th 2018 at 3:22 AM

Fibrosarcoma is cancer, which is a part of larger collection of cancers known as sarcomas. Fibrosarcoma is generally treated with the help of chemotherapy. Meanwhile, some fibrosarcoma is not treatable with chemotherapy, especially in the case where cancer has spread to the parts like liver. In order to treat such type of cancers, researchers are focusing on developing targeted therapies. These targeted therapies attempt to capitalize on the biological characteristic of a cancer cell to eradicate the tumor. This is the factor that will make targeted therapy more effective than the traditional treatments. There are two important reasons for the development of targeted therapy. One is that it targets only cancer cells and kills it, while normal cells can spread. Second is that it provides effective treatment with minimum side-effects. Pharmaceutical companies are also focusing on research and development of drugs that can be effective in the treatment of fibrosarcoma and other types of sarcomas.

As per the new report by Fact.MR, the global fibrosarcoma market is likely to witness steady growth between 2017 and 2026. The market is estimated to reach US$ 442.4 million revenue by 2026 end. Owing to the increasing prevalence of cancer, the use of cancer treatment drugs along with the radiotherapy and chemotherapy is witnessing a significant growth. However, increasing use of radiotherapy to treat various cancers is resulting in the fibrosarcoma. This is leading to the growth in the research activities to find out an effective way to treat cancer.

Chemotherapy to Emerge as the Highly Preferred Treatment Type

Among various treatment types such as radiation therapy, surgery, and others, chemotherapy is likely to emerge as the highly preferred treatment for fibrosarcoma. Chemotherapy is estimated to surpass US$ 100 million by 2026 end. A chemotherapy is done before surgery in case if the cancer is large but has not spread. This helps in reducing fibrosarcoma and also helps in avoiding much surgery.

Hospitals to Gain Maximum Revenue Share

Hospitals are likely to witness the highest growth between 2017 and 2026.  Hospitals are estimated to gain nearly two-fifth of the revenue share by 2017 end. Hospitals are also estimated to create an incremental opportunity of nearly US$ 100 million between 2017 and 2026. Increasing investment by governments in various countries towards the development of healthcare infrastructure is contributing towards the significant growth of the hospitals with technically advanced treatments.

For more information on this report, please visit: https://www.factmr.com/report/353/fibrosarcoma-market

Hospital Pharmacy to Emerge as One of the Largest Distributors

Hospital pharmacy is likely to be one of the largest distribution channels in the global fibrosarcoma market during 2017-2026. Hospital pharmacy is projected to bring in nearly US$ 200 million revenue towards 2026 end. Hospital pharmacy in many countries is emerging as the biggest distributors of the drugs used in treating cancer. Moreover, availability of various drugs and government support are also resulting in the growth of the hospital pharmacy as a distribution channel.

Competition Tracking

The report offers information on the key companies that are likely to play an active role in the expansion of global fibrosarcoma market through 2026, which include Cadila Pharmaceuticals Limited, Celon Laboratories Limited, Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Limited, Sun Pharmaceutical Industries Limited, Novartis AG, Baxter International Inc., Eli Lilly and Company, Pfizer Inc., and Johnson & Johnson.

0 comments
Please to comment

sign in

Username
Password
Remember Me


New to IM faceplate? join free!

Lost Password? click here